Stay updated with breaking news from Nasdaq Espr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […]
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following...
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has received a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among […]
PSI Advisors LLC lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 161.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 shares of the biopharmaceutical company’s stock after purchasing an additional 10,500 shares during the […]
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at […]